SPECIAL ISSUE GUEST-EDITORS: 

Sâmia Joca, Aarhus University, Denmark and Francisco Guimarães, University of São Paulo, Brazil

During the past decade, scientific knowledge on the role of endocannabinoids in different brain mechanisms has significantly inceased, advancing our understanding of the neurobiology of psychiatric disorders and pointing towards new perspectives for innovative treatments. The endocannabinoid system (ECS) can be viewed as fine-tunning modulatory system of brain activity, functional connectivity and neuroplasticity, thus influencing neuronal circuits relevant for different mental disorders. Moreover, preclinical and clinical studies have shown a potential therapeutic effect of cannabinoids in anxiety, depression and schizophrenia, social phobia, personality disorders, bipolar disorders, and post-traumatic stress disorder.

This issue will gather overviews and novel data on cannabinoids (natural, endogenous and synthetic) and psychiatric disorders, based on in vivo (animal and human),ex vivo and in vitro experimental approaches. Human clinical trials, case reports and systematic reviews are encouraged. 

We are excited to invite you to contribute to this special issue of Acta Neuropsychiatrica. We welcome both review articles and empirical papers, including submissions from all types of research, including epidemiology, mechanisms, brain imaging, immune function, therapeutic potential, cognition, and regulatory issues. 

Learn more about how to submit here.

Final submissions will be due April 1st 2023. 

All submissions will be peer-reviewed.